Pharmaceutical Preparations
383 stocks in Healthcare & Pharma · SIC 2834.
Company snapshot 2026-11-13 · Calculated market cap as of 2026-11-06 · USD
| Ticker | Company | Market Cap | Revenue (TTM) | Net Income (TTM) |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.28T | $86.46BTTM ended 2026-09-30 | $27.58BTTM ended 2026-09-30 |
| JNJ | JOHNSON & JOHNSON | $655.56B | $99.33BTTM ended 2026-09-27 | $16.09BTTM ended 2026-09-27 |
| ABBV | AbbVie Inc. | $509.50B | $66.01BTTM ended 2026-09-30 | $10.34BTTM ended 2026-09-30 |
| MRK | Merck & Co., Inc. | $362.24B | $67.38BTTM ended 2026-09-30 | $2.45BTTM ended 2026-09-30 |
| ABT | ABBOTT LABORATORIES | $196.75B | $48.23BTTM ended 2026-09-30 | $4.70BTTM ended 2026-09-30 |
| PFE | PFIZER INC | $170.31B | $63.62BTTM ended 2026-09-27 | $4.03BTTM ended 2026-09-27 |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $137.54B | $12.95BTTM ended 2026-09-30 | $3.98BTTM ended 2026-09-30 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.04B | $50.03BTTM ended 2026-09-30 | $9.24BTTM ended 2026-09-30 |
| REGN | REGENERON PHARMACEUTICALS, INC. | $93.40B | $16.90BTTM ended 2026-09-30 | $4.82BTTM ended 2026-09-30 |
| ZTS | Zoetis Inc. | $33.36B | $9.49BTTM ended 2026-09-30 | $2.51BTTM ended 2026-09-30 |
| ROIV | Roivant Sciences Ltd. | $26.45B | $7.53MTTM ended 2026-06-30 | −$266.25MTTM ended 2026-06-30 |
| UTHR | UNITED THERAPEUTICS Corp | $24.09B | $3.19BTTM ended 2026-09-30 | $1.23BTTM ended 2026-09-30 |
| INSM | INSMED Inc | $23.86B | $1.52BTTM ended 2026-09-30 | −$605.61MTTM ended 2026-09-30 |
| VTRS | Viatris Inc | $21.75B | $14.68BTTM ended 2026-09-30 | −$3.51BTTM ended 2025-12-31 |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $20.98B | $5.01BTTM ended 2026-09-30 | $2.65BTTM ended 2026-09-30 |
| JAZZ | Jazz Pharmaceuticals plc | $14.59B | $4.72BTTM ended 2026-09-30 | $205.95MTTM ended 2026-09-30 |
| BBIO | BridgeBio Pharma, Inc. | $14.47B | $945.54MTTM ended 2026-09-30 | −$577.58MTTM ended 2026-09-30 |
| ELAN | Elanco Animal Health Inc | $11.83B | $5.15BTTM ended 2026-09-30 | −$147.00MTTM ended 2026-09-30 |
| SMMT | Summit Therapeutics Inc. | $11.35B | — | −$832.68MTTM ended 2026-09-30 |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.87B | $3.66BTTM ended 2026-09-30 | −$19.11MTTM ended 2026-09-30 |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $9.29B | $1.43BTTM ended 2026-09-30 | −$155.46MTTM ended 2026-09-30 |
| SYRE | Spyre Therapeutics, Inc. | $9.17B | $0.00TTM ended 2025-12-31 | −$263.86MTTM ended 2026-09-30 |
| TGTX | TG THERAPEUTICS, INC. | $8.87B | $799.54MTTM ended 2026-06-30 | $441.49MTTM ended 2026-06-30 |
| PTGX | Protagonist Therapeutics, Inc | $8.75B | $74.06MTTM ended 2026-03-31 | $342.26MTTM ended 2026-09-30 |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $8.12B | $669.50MTTM ended 2026-06-30 | −$319.95MTTM ended 2026-06-30 |
| CORT | CORCEPT THERAPEUTICS INC | $7.84B | $963.65MTTM ended 2026-09-30 | $162.29MTTM ended 2026-09-30 |
| CYTK | CYTOKINETICS INC | $7.74B | $113.29MTTM ended 2026-09-30 | −$777.89MTTM ended 2026-09-30 |
| ALKS | Alkermes plc. | $7.48B | $1.75BTTM ended 2026-09-30 | −$351.00KTTM ended 2026-09-30 |
| PRAX | Praxis Precision Medicines, Inc. | $7.33B | $0.00TTM ended 2025-12-31 | −$339.13MTTM ended 2026-06-30 |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.28B | $280.75MTTM ended 2026-09-30 | −$193.81MTTM ended 2026-09-30 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.94B | $945.96MTTM ended 2026-09-30 | $109.57MTTM ended 2026-09-30 |
| AXSM | Axsome Therapeutics, Inc. | $6.83B | $865.27MTTM ended 2026-09-30 | −$157.29MTTM ended 2026-09-30 |
| IONS | IONIS PHARMACEUTICALS INC | $6.45B | $874.09MTTM ended 2026-06-30 | −$565.17MTTM ended 2026-06-30 |
| ORKA | Oruka Therapeutics, Inc. | $6.36B | — | −$132.89MTTM ended 2026-06-30 |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.21B | $3.12BTTM ended 2026-06-30 | $157.36MTTM ended 2026-06-30 |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.11B | $670.78MTTM ended 2026-09-30 | −$903.88MTTM ended 2026-09-30 |
| LGND | LIGAND PHARMACEUTICALS INC | $5.98B | $253.83MTTM ended 2026-09-30 | $51.46MTTM ended 2026-09-30 |
| PTCT | PTC THERAPEUTICS, INC. | $5.49B | $1.16BTTM ended 2026-09-30 | −$105.97MTTM ended 2026-09-30 |
| MANE | Veradermics, Inc | $5.37B | — | −$92.68MTTM ended 2026-06-30 |
| COGT | Cogent Biosciences, Inc. | $5.15B | — | −$407.68MTTM ended 2026-09-30 |
| TVTX | Travere Therapeutics, Inc. | $4.69B | $651.03MTTM ended 2026-09-30 | −$121.51MTTM ended 2026-09-30 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.67B | $2.04MTTM ended 2025-12-31 | −$202.12MTTM ended 2026-09-30 |
| ERAS | Erasca, Inc. | $4.64B | — | −$287.22MTTM ended 2026-06-30 |
| INDV | Indivior Pharmaceuticals, Inc. | $4.28B | $1.37BTTM ended 2026-09-30 | $450.00MTTM ended 2026-09-30 |
| EWTX | Edgewise Therapeutics, Inc. | $4.26B | — | $1.01BTTM ended 2026-09-30 |
| LQDA | Liquidia Corp | $3.98B | $450.91MTTM ended 2026-06-30 | $138.61MTTM ended 2026-06-30 |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.67B | $1.20BTTM ended 2026-09-30 | $362.23MTTM ended 2026-09-30 |
| OGN | Organon & Co. | $3.62B | $6.10BTTM ended 2026-09-30 | $213.00MTTM ended 2026-09-30 |
| IRON | Disc Medicine, Inc. | $3.57B | — | −$243.10MTTM ended 2026-09-30 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.55B | $0.00TTM ended 2025-12-31 | −$163.19MTTM ended 2026-09-30 |
| TNGX | Tango Therapeutics, Inc. | $3.52B | $53.81MTTM ended 2026-06-30 | −$123.72MTTM ended 2026-06-30 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.41B | $508.68MTTM ended 2026-09-30 | $29.91MTTM ended 2026-09-30 |
| ELVN | Enliven Therapeutics, Inc. | $3.30B | — | −$113.48MTTM ended 2026-09-30 |
| VKTX | Viking Therapeutics, Inc. | $3.29B | $0.00TTM ended 2026-09-30 | −$627.20MTTM ended 2026-09-30 |
| DYN | Dyne Therapeutics, Inc. | $3.25B | — | −$604.92MTTM ended 2026-09-30 |
| VRDN | Viridian Therapeutics, Inc.DE | $3.24B | $26.31MTTM ended 2026-09-30 | −$453.58MTTM ended 2026-09-30 |
| BHC | Bausch Health Companies Inc. | $2.98B | $11.11BTTM ended 2026-09-30 | −$841.00MTTM ended 2026-09-30 |
| IDYA | IDEAYA Biosciences, Inc. | $2.96B | $36.54MTTM ended 2026-09-30 | −$420.01MTTM ended 2026-09-30 |
| XNCR | Xencor Inc | $2.56B | $200.49MTTM ended 2026-09-30 | −$117.86MTTM ended 2026-09-30 |
| RCUS | Arcus Biosciences, Inc. | $2.55B | $100.00MTTM ended 2026-09-30 | −$453.00MTTM ended 2026-09-30 |
| XERS | Xeris Biopharma Holdings, Inc. | $2.39B | $368.26MTTM ended 2026-09-30 | −$6.50MTTM ended 2026-09-30 |
| MBX | MBX Biosciences, Inc. | $2.33B | — | −$104.29MTTM ended 2026-06-30 |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.29B | — | −$74.99MTTM ended 2026-09-30 |
| NAMS | NewAmsterdam Pharma Co N.V. | $2.27B | $25.94MTTM ended 2026-09-30 | −$204.89MTTM ended 2026-09-30 |
| SEPN | Septerna, Inc. | $2.21B | $98.88MTTM ended 2026-06-30 | −$24.24MTTM ended 2026-06-30 |
| PRGO | PERRIGO Co plc | $2.18B | $4.09BTTM ended 2026-09-26 | −$1.77BTTM ended 2026-09-26 |
| VERA | Vera Therapeutics, Inc. | $2.18B | — | −$415.31MTTM ended 2026-09-30 |
| SDGR | Schrodinger, Inc. | $2.16B | $269.20MTTM ended 2026-09-30 | −$59.25MTTM ended 2026-09-30 |
| PBH | Prestige Consumer Healthcare Inc. | $2.10B | $1.17BTTM ended 2026-09-30 | $155.10MTTM ended 2026-09-30 |
| BHVN | Biohaven Ltd. | $2.10B | — | −$542.68MTTM ended 2026-09-30 |
| ZYME | Zymeworks Inc. | $2.04B | $37.13MTTM ended 2026-06-30 | −$149.99MTTM ended 2026-06-30 |
| IMNM | Immunome Inc. | $2.03B | $0.00TTM ended 2026-06-30 | −$254.32MTTM ended 2026-06-30 |
| HRMY | Harmony Biosciences Holdings, Inc. | $1.91B | $989.36MTTM ended 2026-09-30 | $178.60MTTM ended 2026-09-30 |
| SRPT | Sarepta Therapeutics, Inc. | $1.88B | $1.96BTTM ended 2026-09-30 | −$114.62MTTM ended 2026-09-30 |
| TRVI | Trevi Therapeutics, Inc. | $1.83B | — | −$51.11MTTM ended 2026-06-30 |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $1.81B | $213.00MTTM ended 2026-09-30 | −$65.67MTTM ended 2026-09-30 |
| ZBIO | Zenas BioPharma, Inc. | $1.76B | $11.00MTTM ended 2026-09-30 | −$541.81MTTM ended 2026-09-30 |
| STOK | Stoke Therapeutics, Inc. | $1.71B | $28.21MTTM ended 2026-09-30 | −$243.20MTTM ended 2026-09-30 |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.69B | $140.84MTTM ended 2026-09-30 | −$372.90MTTM ended 2026-09-30 |
| NRIX | Nurix Therapeutics, Inc. | $1.62B | $701.94MTTM ended 2026-08-31 | $294.88MTTM ended 2026-08-31 |
| SLS | SELLAS Life Sciences Group, Inc. | $1.59B | — | −$32.46MTTM ended 2026-06-30 |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.59B | $730.00MTTM ended 2026-09-30 | −$524.00MTTM ended 2026-09-30 |
| ANIP | ANI PHARMACEUTICALS INC | $1.58B | $1.04BTTM ended 2026-09-30 | $116.84MTTM ended 2026-09-30 |
| BRVE | Braveheart Bio, Inc. | $1.57B | — | — |
| PGEN | PRECIGEN, INC. | $1.51B | $156.94MTTM ended 2026-09-30 | $24.41MTTM ended 2026-09-30 |
| NUVB | Nuvation Bio Inc. | $1.48B | $201.73MTTM ended 2026-09-30 | −$135.93MTTM ended 2026-09-30 |
| QURE | uniQure N.V. | $1.47B | $16.10MTTM ended 2025-12-31 | −$232.90MTTM ended 2026-09-30 |
| PCRX | Pacira BioSciences, Inc. | $1.46B | $743.30MTTM ended 2026-09-30 | $37.73MTTM ended 2026-09-30 |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.44B | $1.54BTTM ended 2026-09-30 | $102.71MTTM ended 2026-09-30 |
| OCUL | OCULAR THERAPEUTIX, INC | $1.41B | $52.05MTTM ended 2026-06-30 | −$301.45MTTM ended 2026-06-30 |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | — | −$150.47MTTM ended 2026-09-30 |
| INVA | Innoviva, Inc. | $1.37B | $438.32MTTM ended 2026-09-30 | $193.44MTTM ended 2026-09-30 |
| ETON | Eton Pharmaceuticals, Inc. | $1.36B | $141.06MTTM ended 2026-09-30 | $49.86MTTM ended 2026-09-30 |
| DMRA | Damora Therapeutics, Inc. | $1.35B | — | −$291.68MTTM ended 2026-09-30 |
| MLYS | Mineralys Therapeutics, Inc. | $1.35B | — | −$369.97MTTM ended 2026-09-30 |
| ANAB | ANAPTYSBIO, INC | $1.33B | $232.39MTTM ended 2026-03-31 | −$26.79MTTM ended 2026-03-31 |
| OPK | OPKO HEALTH, INC. | $1.30B | $654.10MTTM ended 2026-09-30 | −$148.06MTTM ended 2026-09-30 |
| TYRA | Tyra Biosciences, Inc. | $1.25B | — | −$148.56MTTM ended 2026-06-30 |
| OMER | OMEROS CORP | $1.24B | — | $124.83MTTM ended 2026-06-30 |
| NKTR | NEKTAR THERAPEUTICS | $1.23B | $54.59MTTM ended 2026-06-30 | −$157.13MTTM ended 2026-06-30 |
| LBRX | LB PHARMACEUTICALS INC | $1.23B | — | −$141.19MTTM ended 2026-09-30 |
| MNKD | MANNKIND CORP | $1.21B | $413.37MTTM ended 2026-09-30 | −$74.82MTTM ended 2026-09-30 |
| VSTM | Verastem, Inc. | $1.18B | $100.30MTTM ended 2026-09-30 | −$178.90MTTM ended 2026-09-30 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.18B | $745.79MTTM ended 2026-09-30 | $98.96MTTM ended 2026-09-30 |
| JANX | Janux Therapeutics, Inc. | $982.61M | $23.29MTTM ended 2026-09-30 | −$99.85MTTM ended 2026-09-30 |
| HROW | HARROW, INC. | $976.18M | $275.59MTTM ended 2026-06-30 | −$37.23MTTM ended 2026-06-30 |
| MLTX | MoonLake Immunotherapeutics | $919.15M | — | −$273.48MTTM ended 2026-09-30 |
| SVRA | Savara Inc | $899.91M | — | −$139.31MTTM ended 2026-06-30 |
| JBIO | Jade Biosciences, Inc. | $896.72M | — | −$153.24MTTM ended 2026-06-30 |
| ORIC | Oric Pharmaceuticals, Inc. | $880.01M | — | −$140.35MTTM ended 2026-06-30 |
| RIGL | RIGEL PHARMACEUTICALS INC | $860.72M | $288.21MTTM ended 2026-09-30 | $307.19MTTM ended 2026-09-30 |
| ANRO | Alto Neuroscience, Inc. | $858.22M | — | −$84.24MTTM ended 2026-06-30 |
| SNDX | Syndax Pharmaceuticals Inc | $826.44M | $289.68MTTM ended 2026-09-30 | −$209.48MTTM ended 2026-09-30 |
| CRVS | Corvus Pharmaceuticals, Inc. | $820.76M | — | −$64.31MTTM ended 2026-09-30 |
| CYRX | Cryoport, Inc. | $813.74M | $192.44MTTM ended 2026-09-30 | −$41.30MTTM ended 2026-09-30 |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $781.86M | $815.19MTTM ended 2026-09-30 | $38.17MTTM ended 2026-09-30 |
| ANNX | Annexon, Inc. | $759.26M | — | −$202.67MTTM ended 2026-06-30 |
| ALMS | ALUMIS INC. | $757.20M | $7.40MTTM ended 2026-06-30 | −$438.96MTTM ended 2026-06-30 |
| ARDX | ARDELYX, INC. | $751.60M | $468.22MTTM ended 2026-09-30 | −$55.47MTTM ended 2026-09-30 |
| ABUS | Arbutus Biopharma Corp | $726.10M | $181.72MTTM ended 2026-06-30 | $153.05MTTM ended 2026-06-30 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $716.83M | $38.54MTTM ended 2026-09-30 | −$62.35MTTM ended 2026-09-30 |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $667.17M | $400.30MTTM ended 2026-09-30 | $149.63MTTM ended 2026-09-30 |
| WVE | Wave Life Sciences Ltd. | $635.08M | $70.92MTTM ended 2026-09-30 | −$210.53MTTM ended 2026-09-30 |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $626.58M | $147.76MTTM ended 2026-09-30 | $78.02MTTM ended 2026-09-30 |
| DSGN | Design Therapeutics, Inc. | $619.23M | $0.00TTM ended 2026-09-30 | −$74.09MTTM ended 2026-09-30 |
| GERN | GERON CORP | $612.03M | — | −$47.83MTTM ended 2026-09-30 |
| NVCT | Nuvectis Pharma, Inc. | $610.75M | — | −$50.45MTTM ended 2026-09-30 |
| KURA | Kura Oncology, Inc. | $604.93M | $77.22MTTM ended 2026-06-30 | −$296.77MTTM ended 2026-06-30 |
| AVBP | ArriVent BioPharma, Inc. | $603.03M | — | −$163.74MTTM ended 2026-06-30 |
| OLMA | Olema Pharmaceuticals, Inc. | $591.48M | — | −$204.57MTTM ended 2026-06-30 |
| ACRS | Aclaris Therapeutics, Inc. | $572.59M | $6.40MTTM ended 2026-09-30 | −$79.63MTTM ended 2026-09-30 |
| SGMT | Sagimet Biosciences Inc. | $566.89M | — | −$47.08MTTM ended 2026-06-30 |
| BCAX | Bicara Therapeutics Inc. | $541.96M | — | −$185.36MTTM ended 2026-06-30 |
| CLYM | Climb Bio, Inc. | $521.01M | — | −$59.31MTTM ended 2026-09-30 |
| IMMX | Immix Biopharma, Inc. | $515.08M | — | −$39.92MTTM ended 2026-06-30 |
| SNSE | Sensei Biotherapeutics, Inc. | $514.74M | — | −$211.36MTTM ended 2026-09-30 |
| NGNE | Neurogene Inc. | $513.29M | $0.00TTM ended 2025-12-31 | −$111.11MTTM ended 2026-06-30 |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $504.33M | $231.24MTTM ended 2026-06-30 | $26.72MTTM ended 2026-06-30 |
| OVID | Ovid Therapeutics Inc. | $503.87M | $1.58MTTM ended 2026-06-30 | −$34.49MTTM ended 2026-06-30 |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $500.00M | $0.00TTM ended 2025-12-31 | −$129.42MTTM ended 2026-06-30 |
| DMAC | DiaMedica Therapeutics Inc. | $487.49M | — | −$37.54MTTM ended 2026-06-30 |
| CBIO | CRESCENT BIOPHARMA, INC. | $480.64M | $11.88MTTM ended 2026-06-30 | −$165.12MTTM ended 2026-06-30 |
| IBO | IMPACT BIOMEDICAL INC. | $474.41M | $35.00KTTM ended 2026-06-30 | $791.00KTTM ended 2026-06-30 |
| CTMX | CytomX Therapeutics, Inc. | $466.53M | $14.03MTTM ended 2026-09-30 | −$85.42MTTM ended 2026-09-30 |
| AQST | Aquestive Therapeutics, Inc. | $460.02M | $48.84MTTM ended 2026-09-30 | −$79.28MTTM ended 2026-09-30 |
| STTK | Shattuck Labs, Inc. | $457.27M | $0.00TTM ended 2026-09-30 | −$67.72MTTM ended 2026-09-30 |
| MNPR | Monopar Therapeutics | $451.19M | $0.00TTM ended 2025-12-31 | −$17.84MTTM ended 2026-06-30 |
| EOLS | Evolus, Inc. | $449.75M | $325.47MTTM ended 2026-09-30 | −$31.11MTTM ended 2026-09-30 |
| GYRE | GYRE THERAPEUTICS, INC. | $447.15M | $110.06MTTM ended 2026-09-30 | −$36.62MTTM ended 2026-09-30 |
| ARVN | ARVINAS, INC. | $428.93M | $262.60MTTM ended 2025-12-31 | −$9.50MTTM ended 2026-09-30 |
| INDP | Indaptus Therapeutics, Inc. | $421.05M | — | −$15.42MTTM ended 2026-06-30 |
| PHAT | Phathom Pharmaceuticals, Inc. | $412.96M | $274.88MTTM ended 2026-09-30 | −$83.00MTTM ended 2026-09-30 |
| CRMD | CorMedix Inc. | $407.65M | $311.71MTTM ended 2025-12-31 | $187.17MTTM ended 2026-06-30 |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $407.21M | $72.30MTTM ended 2025-12-31 | −$42.00KTTM ended 2026-06-30 |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $405.15M | $52.73MTTM ended 2026-09-30 | −$23.96MTTM ended 2026-09-30 |
| RLMD | RELMADA THERAPEUTICS, INC. | $402.15M | — | −$61.93MTTM ended 2026-06-30 |
| AVTX | Avalo Therapeutics, Inc. | $383.37M | $59.00KTTM ended 2025-12-31 | −$88.65MTTM ended 2026-09-30 |
| ALT | Altimmune, Inc. | $383.20M | $41.00KTTM ended 2025-12-31 | −$91.76MTTM ended 2026-06-30 |
| LYEL | Lyell Immunopharma, Inc. | $368.78M | $15.00KTTM ended 2026-09-30 | −$255.16MTTM ended 2026-09-30 |
| RZLT | Rezolute, Inc. | $352.09M | — | −$77.92MTTM ended 2026-09-30 |
| CTNM | Contineum Therapeutics, Inc. | $345.93M | — | −$63.46MTTM ended 2026-09-30 |
| AVIR | Atea Pharmaceuticals, Inc. | $338.46M | — | −$165.29MTTM ended 2026-06-30 |
| IRD | Opus Genetics, Inc. | $333.62M | $9.86MTTM ended 2026-06-30 | −$107.61MTTM ended 2026-06-30 |
| GALT | GALECTIN THERAPEUTICS INC | $301.54M | — | −$27.84MTTM ended 2026-06-30 |
| BNTC | Benitec Biopharma Inc. | $301.39M | — | −$45.55MTTM ended 2026-06-30 |
| EBS | Emergent BioSolutions Inc. | $300.78M | $649.10MTTM ended 2026-09-30 | −$260.70MTTM ended 2026-09-30 |
| ENTA | ENANTA PHARMACEUTICALS INC | $293.58M | $65.26MTTM ended 2026-06-30 | −$63.23MTTM ended 2026-06-30 |
| MPLT | MapLight Therapeutics, Inc. | $288.47M | — | −$229.83MTTM ended 2026-06-30 |
| PRLD | Prelude Therapeutics Inc | $283.70M | $22.42MTTM ended 2026-06-30 | −$60.49MTTM ended 2026-06-30 |
| FULC | Fulcrum Therapeutics, Inc. | $280.77M | $0.00TTM ended 2025-12-31 | −$85.00MTTM ended 2026-06-30 |
| ARCT | Arcturus Therapeutics Holdings Inc. | $269.78M | $30.51MTTM ended 2026-09-30 | −$87.24MTTM ended 2026-09-30 |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $267.30M | $0.00TTM ended 2026-06-30 | −$17.25MTTM ended 2026-06-30 |
| SPRY | ARS Pharmaceuticals, Inc. | $266.40M | $122.14MTTM ended 2026-09-30 | −$199.87MTTM ended 2026-09-30 |
| TTRX | Turn Therapeutics Inc. | $266.31M | — | −$8.45MTTM ended 2026-06-30 |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $266.18M | — | −$877.00KTTM ended 2026-06-30 |
| QTTB | Q32 Bio Inc. | $264.83M | $53.74MTTM ended 2025-12-31 | $32.25MTTM ended 2026-09-30 |
| BIOA | BioAge Labs, Inc. | $254.61M | $8.60MTTM ended 2026-09-30 | −$107.80MTTM ended 2026-09-30 |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $242.60M | $128.87MTTM ended 2025-05-25 | −$38.72MTTM ended 2025-05-25 |
| LRMR | Larimar Therapeutics, Inc. | $241.01M | — | −$172.60MTTM ended 2026-06-30 |
| CAMP | Camp4 Therapeutics Corp | $233.45M | $5.32MTTM ended 2026-09-30 | −$121.10MTTM ended 2026-09-30 |
| EVMN | Evommune, Inc. | $231.18M | $10.00MTTM ended 2026-06-30 | −$94.67MTTM ended 2026-06-30 |
| ABEO | ABEONA THERAPEUTICS INC. | $223.59M | $25.52MTTM ended 2026-06-30 | −$62.89MTTM ended 2026-06-30 |
| IMRX | Immuneering Corp | $218.25M | — | −$66.50MTTM ended 2026-09-30 |
| VNDA | Vanda Pharmaceuticals Inc. | $217.09M | $229.28MTTM ended 2026-09-30 | −$274.83MTTM ended 2026-09-30 |
| GLSI | Greenwich LifeSciences, Inc. | $215.04M | — | −$22.47MTTM ended 2026-06-30 |
| SIGA | SIGA TECHNOLOGIES INC | $213.39M | $53.66MTTM ended 2026-06-30 | −$2.79MTTM ended 2026-06-30 |
| ADCT | ADC Therapeutics SA | $209.38M | $79.58MTTM ended 2026-06-30 | −$96.91MTTM ended 2026-06-30 |
| RNAC | Cartesian Therapeutics, Inc. | $206.81M | $1.02MTTM ended 2026-09-30 | −$127.46MTTM ended 2026-09-30 |
| GTBP | GT Biopharma, Inc. | $204.80M | — | −$4.76MTTM ended 2026-06-30 |
| KRRO | Korro Bio, Inc. | $202.18M | $1.29MTTM ended 2026-09-30 | −$106.13MTTM ended 2026-09-30 |
| ELDN | Eledon Pharmaceuticals, Inc. | $199.90M | — | −$98.56MTTM ended 2026-06-30 |
| PYXS | Pyxis Oncology, Inc. | $192.57M | $13.86MTTM ended 2025-12-31 | −$86.71MTTM ended 2026-09-30 |
| KROS | Keros Therapeutics, Inc. | $185.45M | $40.76MTTM ended 2026-09-30 | −$61.73MTTM ended 2026-09-30 |
| CURX | Curanex Pharmaceuticals Inc | $181.29M | — | −$10.47MTTM ended 2026-06-30 |
| TRDA | Entrada Therapeutics, Inc. | $178.13M | $3.98MTTM ended 2026-09-30 | −$161.39MTTM ended 2026-09-30 |
| NATR | NATURES SUNSHINE PRODUCTS INC | $177.79M | $480.29MTTM ended 2026-09-30 | $14.65MTTM ended 2026-09-30 |
| UPB | Upstream Bio, Inc. | $175.82M | $3.16MTTM ended 2026-06-30 | −$156.50MTTM ended 2026-06-30 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $173.98M | — | −$182.11MTTM ended 2026-06-30 |
| WHWK | Whitehawk Therapeutics, Inc. | $172.17M | $0.00TTM ended 2026-06-30 | −$79.83MTTM ended 2026-06-30 |
| MBRX | Moleculin Biotech, Inc. | $170.04M | $0.00TTM ended 2026-06-30 | −$30.33MTTM ended 2026-06-30 |
| ORMP | ORAMED PHARMACEUTICALS INC. | $161.81M | $2.00MTTM ended 2025-12-31 | $174.87MTTM ended 2026-06-30 |
| PEPG | PepGen Inc. | $160.68M | — | −$71.94MTTM ended 2026-06-30 |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $159.02M | — | −$80.89MTTM ended 2026-06-30 |
| CNTN | Canton Strategic Holdings, Inc. | $153.79M | — | −$98.12MTTM ended 2026-06-30 |
| INO | INOVIO PHARMACEUTICALS, INC. | $149.93M | $0.00TTM ended 2026-06-30 | −$67.43MTTM ended 2026-06-30 |
| ANTX | AN2 Therapeutics, Inc. | $149.25M | — | −$36.27MTTM ended 2026-06-30 |
| SION | Sionna Therapeutics, Inc. | $148.30M | — | −$97.38MTTM ended 2026-06-30 |
| CYCN | Cyclerion Therapeutics, Inc. | $142.45M | $1.90MTTM ended 2026-06-30 | −$58.88MTTM ended 2026-09-30 |
| MGNX | MACROGENICS INC | $141.41M | $175.14MTTM ended 2026-06-30 | −$14.59MTTM ended 2026-06-30 |
| CUE | Cue Biopharma, Inc. | $130.83M | $37.66MTTM ended 2026-06-30 | −$164.11MTTM ended 2026-06-30 |
| SCNX | Scienture Holdings, Inc. | $127.30M | $821.32KTTM ended 2026-06-30 | −$37.95MTTM ended 2026-06-30 |
| SPRB | SPRUCE BIOSCIENCES, INC. | $122.75M | $0.00TTM ended 2025-12-31 | −$51.35MTTM ended 2026-06-30 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $122.56M | $0.00TTM ended 2025-12-31 | −$139.54MTTM ended 2026-06-30 |
| DERM | Journey Medical Corp | $121.36M | $68.18MTTM ended 2026-06-30 | −$6.10MTTM ended 2026-06-30 |
| AKBA | Akebia Therapeutics, Inc. | $118.15M | $197.20MTTM ended 2026-09-30 | −$44.56MTTM ended 2026-09-30 |
| MDCX | Medicus Pharma Ltd. | $115.62M | — | −$50.91MTTM ended 2026-09-30 |
| FHTX | Foghorn Therapeutics Inc. | $113.13M | $36.74MTTM ended 2026-06-30 | −$64.58MTTM ended 2026-06-30 |
| NKTX | Nkarta, Inc. | $112.58M | $0.00TTM ended 2025-12-31 | −$128.94MTTM ended 2026-09-30 |
| NERV | Minerva Neurosciences, Inc. | $109.82M | — | −$290.86MTTM ended 2026-09-30 |
| ORGO | Organogenesis Holdings Inc. | $109.03M | $352.05MTTM ended 2026-09-30 | −$135.35MTTM ended 2026-09-30 |
| ANIX | Anixa Biosciences Inc | $105.33M | — | −$10.38MTTM ended 2026-07-31 |
| HURA | TuHURA Biosciences, Inc./NV | $102.60M | $0.00TTM ended 2026-03-31 | −$30.62MTTM ended 2026-06-30 |
| OKUR | OnKure Therapeutics, Inc. | $102.27M | — | −$61.85MTTM ended 2026-09-30 |
| IMUX | IMMUNIC, INC. | $99.88M | — | −$111.57MTTM ended 2026-06-30 |
| NRXP | NRX Pharmaceuticals, Inc. | $98.28M | $3.39MTTM ended 2026-06-30 | −$23.48MTTM ended 2026-06-30 |
| UNCY | Unicycive Therapeutics, Inc. | $96.94M | — | −$35.22MTTM ended 2026-06-30 |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $92.32M | $0.00TTM ended 2026-09-30 | −$43.02MTTM ended 2026-09-30 |
| CATX | Perspective Therapeutics, Inc. | $90.18M | — | −$116.43MTTM ended 2026-06-30 |
| VTVT | vTv Therapeutics Inc. | $87.21M | $36.84MTTM ended 2026-09-30 | −$7.68MTTM ended 2026-09-30 |
| PLYX | Polaryx Therapeutics, Inc. | $86.73M | — | −$6.85MTTM ended 2026-06-30 |
| RLYB | Rallybio Corp | $84.47M | $434.00KTTM ended 2026-09-30 | $26.81MTTM ended 2026-09-30 |
| EQ | Equillium, Inc. | $84.33M | — | −$18.01MTTM ended 2026-06-30 |
| GNLX | GENELUX Corp | $82.35M | $8.00KTTM ended 2025-12-31 | −$35.60MTTM ended 2026-06-30 |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $78.89M | $29.10MTTM ended 2026-06-30 | −$159.67MTTM ended 2026-06-30 |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $75.07M | $39.90MTTM ended 2026-06-30 | −$10.92MTTM ended 2026-06-30 |
| TENX | TENAX THERAPEUTICS, INC. | $74.22M | $0.00TTM ended 2026-09-30 | −$65.76MTTM ended 2026-09-30 |
| RANI | Rani Therapeutics Holdings, Inc. | $71.93M | $4.88MTTM ended 2026-06-30 | −$30.14MTTM ended 2026-06-30 |
| MNOV | MEDICINOVA INC | $71.37M | $920.48KTTM ended 2026-06-30 | −$10.75MTTM ended 2026-06-30 |
| PMVP | PMV Pharmaceuticals, Inc. | $68.16M | — | −$75.22MTTM ended 2026-06-30 |
| ACRV | Acrivon Therapeutics, Inc. | $67.28M | — | −$74.22MTTM ended 2026-06-30 |
| COYA | Coya Therapeutics, Inc. | $65.92M | $8.02MTTM ended 2026-06-30 | −$21.67MTTM ended 2026-06-30 |
| SDEV | Stablecoin Development Corp | $65.81M | $9.78MTTM ended 2025-09-30 | −$73.54MTTM ended 2026-09-30 |
| PDSB | PDS Biotechnology Corp | $65.49M | — | −$33.67MTTM ended 2026-06-30 |
| LFVN | Lifevantage Corp | $63.26M | $182.59MTTM ended 2026-06-30 | $5.07MTTM ended 2026-06-30 |
| MAIA | MAIA Biotechnology, Inc. | $63.26M | — | −$26.85MTTM ended 2026-06-30 |
| CING | Cingulate Inc. | $61.66M | — | −$28.80MTTM ended 2026-06-30 |
| FBIO | Fortress Biotech, Inc. | $61.37M | $68.47MTTM ended 2026-06-30 | $111.82MTTM ended 2026-06-30 |
| SPRO | Spero Therapeutics, Inc. | $59.40M | $47.00MTTM ended 2026-06-30 | $7.38MTTM ended 2026-06-30 |
| QUCY | Quantum Cyber N.V. | $58.60M | $537.08KTTM ended 2025-12-31 | −$23.83MTTM ended 2026-06-30 |
| GOSS | Gossamer Bio, Inc. | $57.56M | $53.29MTTM ended 2026-06-30 | −$125.22MTTM ended 2026-06-30 |
| RNXT | RenovoRx, Inc. | $57.42M | $2.78MTTM ended 2026-09-30 | −$13.02MTTM ended 2026-09-30 |
| ONCY | ONCOLYTICS BIOTECH INC | $57.38M | — | −$37.46MTTM ended 2026-06-30 |
| CLNN | Clene Inc. | $57.17M | $238.00KTTM ended 2026-09-30 | −$26.83MTTM ended 2026-09-30 |
| XBIT | XBiotech Inc. | $57.01M | — | −$45.13MTTM ended 2026-06-30 |
| LIXT | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | $56.19M | — | −$8.86MTTM ended 2026-06-30 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $55.32M | — | −$101.90MTTM ended 2026-06-30 |
| RFL | Rafael Holdings, Inc. | $55.32M | $874.00KTTM ended 2026-07-31 | −$29.64MTTM ended 2026-07-31 |
| BOLD | Boundless Bio, Inc. | $54.82M | — | −$64.01MTTM ended 2026-06-30 |
| LGVN | Longeveron Inc. | $54.52M | $1.19MTTM ended 2026-06-30 | −$23.47MTTM ended 2026-06-30 |
| TELO | Telomir Pharmaceuticals, Inc. | $53.64M | — | −$5.48MTTM ended 2026-09-30 |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $53.16M | $151.18MTTM ended 2026-06-30 | −$34.05MTTM ended 2026-06-30 |
| VRCA | Verrica Pharmaceuticals Inc. | $53.08M | $30.32MTTM ended 2026-06-30 | −$31.18MTTM ended 2026-06-30 |
| RNTX | Rein Therapeutics, Inc. | $52.80M | $0.00TTM ended 2026-06-30 | −$49.76MTTM ended 2026-06-30 |
| TLPH | TALPHERA, INC. | $52.42M | $1.00KTTM ended 2026-06-30 | −$15.08MTTM ended 2026-06-30 |
| PLRX | PLIANT THERAPEUTICS, INC. | $50.53M | $0.00TTM ended 2025-12-31 | −$92.29MTTM ended 2026-06-30 |
| HOWL | Werewolf Therapeutics, Inc. | $49.57M | — | −$34.61MTTM ended 2026-06-30 |
| XLO | Xilio Therapeutics, Inc. | $49.15M | $64.09MTTM ended 2026-06-30 | −$21.83MTTM ended 2026-06-30 |
| IBIO | iBio, Inc. | $46.94M | $100.00KTTM ended 2026-06-30 | −$33.04MTTM ended 2026-06-30 |
| CTOR | CITIUS ONCOLOGY, INC. | $46.49M | — | −$46.06MTTM ended 2026-06-30 |
| CNTB | Connect Biopharma Holdings Ltd | $46.10M | $2.95MTTM ended 2026-06-30 | −$68.99MTTM ended 2026-06-30 |
| OSTX | OS Therapies Inc | $45.20M | — | −$39.37MTTM ended 2026-06-30 |
| CALC | CalciMedica, Inc. | $44.38M | — | −$21.24MTTM ended 2026-06-30 |
| AZTR | Azitra, Inc. | $43.94M | $0.00TTM ended 2025-12-31 | −$12.27MTTM ended 2026-06-30 |
| BMEA | Biomea Fusion, Inc. | $42.55M | — | −$32.54MTTM ended 2026-06-30 |
| SER | Serina Therapeutics, Inc. | $41.91M | $0.00TTM ended 2026-06-30 | −$21.18MTTM ended 2026-06-30 |
| GANX | Gain Therapeutics, Inc. | $41.90M | — | −$20.11MTTM ended 2026-06-30 |
| ATNM | Actinium Pharmaceuticals, Inc. | $40.87M | $90.00KTTM ended 2025-12-31 | $11.31MTTM ended 2026-06-30 |
| HYPD | HYPERION DEFI, INC. | $39.78M | $1.40MTTM ended 2026-06-30 | $6.65MTTM ended 2026-06-30 |
| ELTX | Elicio Therapeutics, Inc. | $39.63M | — | −$35.74MTTM ended 2026-09-30 |
| GRCE | Grace Therapeutics, Inc. | $37.44M | — | −$20.22MTTM ended 2026-06-30 |
| ALDX | Aldeyra Therapeutics, Inc. | $37.17M | — | −$19.13MTTM ended 2026-09-30 |
| SKYE | Skye Bioscience, Inc. | $36.84M | — | −$50.49MTTM ended 2026-06-30 |
| VYNE | VYNE Therapeutics Inc. | $36.31M | $482.00KTTM ended 2026-06-30 | −$18.71MTTM ended 2026-06-30 |
| DWTX | Dogwood Therapeutics, Inc. | $35.35M | — | −$25.18MTTM ended 2026-09-30 |
| VERU | VERU INC. | $35.12M | — | −$13.61MTTM ended 2026-06-30 |
| GRDX | GridAI Technologies Corp. | $33.30M | $36.25KTTM ended 2025-12-31 | −$20.77MTTM ended 2026-06-30 |
| NNVC | NANOVIRICIDES, INC. | $32.93M | $0.00TTM ended 2026-06-30 | −$8.22MTTM ended 2026-06-30 |
| SCYX | SCYNEXIS INC | $32.85M | $18.88MTTM ended 2026-09-30 | −$10.10MTTM ended 2026-09-30 |
| RMTI | ROCKWELL MEDICAL, INC. | $30.63M | $69.39MTTM ended 2026-06-30 | −$5.08MTTM ended 2026-06-30 |
| LITS | Lite Strategy, Inc. | $28.99M | $0.00TTM ended 2025-06-30 | −$51.49MTTM ended 2026-09-30 |
| ANVS | Annovis Bio, Inc. | $28.50M | $0.00TTM ended 2026-06-30 | −$49.52MTTM ended 2026-06-30 |
| IXHL | Incannex Healthcare Inc. | $28.48M | $0.00TTM ended 2026-06-30 | −$19.30MTTM ended 2026-06-30 |
| ACET | Adicet Bio, Inc. | $27.34M | — | −$91.00MTTM ended 2026-09-30 |
| BYSI | BeyondSpring Inc. | $25.99M | $0.00TTM ended 2026-06-30 | −$6.68MTTM ended 2026-06-30 |
| ABVC | ABVC BIOPHARMA, INC. | $25.88M | $296.00KTTM ended 2025-12-31 | −$7.11MTTM ended 2026-06-30 |
| RNAZ | Transcode Therapeutics, Inc. | $25.57M | — | −$42.83MTTM ended 2026-06-30 |
| AARD | Aardvark Therapeutics, Inc. | $24.29M | $0.00TTM ended 2026-06-30 | −$69.89MTTM ended 2026-06-30 |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $24.01M | — | −$10.26MTTM ended 2026-06-30 |
| CELU | Celularity Inc | $23.53M | $18.67MTTM ended 2026-06-30 | −$45.86MTTM ended 2026-06-30 |
| NXTC | NextCure, Inc. | $23.44M | — | −$42.75MTTM ended 2026-06-30 |
| MIRA | MIRA PHARMACEUTICALS, INC. | $22.69M | — | −$9.48MTTM ended 2026-06-30 |
| FLNA | FILANA THERAPEUTICS, INC. | $22.62M | — | −$42.20MTTM ended 2026-09-30 |
| CRVO | CervoMed Inc. | $21.92M | $8.73KTTM ended 2026-09-30 | −$28.52MTTM ended 2026-09-30 |
| MCRB | Seres Therapeutics, Inc. | $21.31M | $2.12MTTM ended 2026-09-30 | −$46.95MTTM ended 2026-09-30 |
| ATOS | ATOSSA THERAPEUTICS, INC. | $20.16M | — | −$37.71MTTM ended 2026-06-30 |
| TXMD | TherapeuticsMD, Inc. | $19.79M | $3.27MTTM ended 2026-06-30 | −$217.00KTTM ended 2026-06-30 |
| AYTU | AYTU BIOPHARMA, INC | $19.67M | $57.57MTTM ended 2026-06-30 | −$14.25MTTM ended 2026-06-30 |
| IGC | IGC Pharma, Inc. | $19.64M | $1.11MTTM ended 2025-09-30 | −$6.45MTTM ended 2025-09-30 |
| COCP | Cocrystal Pharma, Inc. | $19.26M | — | −$9.94MTTM ended 2026-06-30 |
| KTTA | Pasithea Therapeutics Corp. | $17.38M | — | −$21.29MTTM ended 2026-06-30 |
| CNTX | Context Therapeutics Inc. | $17.27M | — | −$45.96MTTM ended 2026-06-30 |
| LPCN | Lipocine Inc. | $16.94M | $3.74MTTM ended 2026-09-30 | −$9.33MTTM ended 2026-09-30 |
| ALLR | Allarity Therapeutics, Inc. | $15.53M | $345.00KTTM ended 2026-06-30 | −$12.33MTTM ended 2026-06-30 |
| CTXR | Citius Pharmaceuticals, Inc. | $15.29M | — | −$58.17MTTM ended 2026-06-30 |
| MRKR | Marker Therapeutics, Inc. | $15.01M | $3.95MTTM ended 2026-03-31 | −$8.71MTTM ended 2026-06-30 |
| NEUP | Neuphoria Therapeutics Inc. | $14.99M | $1.17MTTM ended 2026-06-30 | −$13.45MTTM ended 2026-06-30 |
| KYNB | KYNTRA BIO, INC. | $14.82M | $4.62MTTM ended 2026-06-30 | $183.19MTTM ended 2026-06-30 |
| ELAB | PMGC Holdings Inc. | $13.36M | $590.08KTTM ended 2025-12-31 | −$13.49MTTM ended 2026-06-30 |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $13.26M | — | −$57.80MTTM ended 2026-06-30 |
| BOLT | Bolt Biotherapeutics, Inc. | $12.29M | $4.70MTTM ended 2026-06-30 | −$28.74MTTM ended 2026-06-30 |
| BFRI | Biofrontera Inc. | $12.00M | $46.17MTTM ended 2026-06-30 | −$6.37MTTM ended 2026-06-30 |
| TVRD | Tvardi Therapeutics, Inc. | $11.54M | — | −$26.06MTTM ended 2026-06-30 |
| HIND | Vyome Holdings, Inc | $11.44M | $129.72KTTM ended 2026-06-30 | −$11.31MTTM ended 2026-06-30 |
| CLRB | Cellectar Biosciences, Inc. | $10.87M | — | −$22.32MTTM ended 2026-06-30 |
| SBFM | Sunshine Biopharma Inc. | $10.82M | $35.35MTTM ended 2026-06-30 | −$5.83MTTM ended 2026-06-30 |
| KAPA | Kairos Pharma, LTD. | $10.78M | — | −$5.80MTTM ended 2026-06-30 |
| PTN | PALATIN TECHNOLOGIES INC | $10.17M | $13.19MTTM ended 2026-06-30 | −$8.38MTTM ended 2026-06-30 |
| RKTO | Rocket One Inc. | $10.01M | — | −$13.32MTTM ended 2026-06-30 |
| ARTL | ARTELO BIOSCIENCES, INC. | $9.72M | — | −$12.67MTTM ended 2026-06-30 |
| PHIO | Phio Pharmaceuticals Corp. | $9.56M | — | −$14.67MTTM ended 2026-09-30 |
| DARE | Dare Bioscience, Inc. | $9.54M | $1.37MTTM ended 2026-06-30 | −$10.99MTTM ended 2026-06-30 |
| ASBP | Aspire Biopharma Holdings, Inc. | $9.48M | $6.20KTTM ended 2025-12-31 | −$11.05MTTM ended 2026-06-30 |
| BFRG | BullFrog AI Holdings, Inc. | $9.14M | $298.80KTTM ended 2026-06-30 | −$6.00MTTM ended 2026-06-30 |
| BIVI | BIOVIE INC. | $9.13M | — | −$22.59MTTM ended 2026-09-30 |
| LSTA | LISATA THERAPEUTICS, INC. | $8.92M | $100.00KTTM ended 2026-06-30 | −$14.62MTTM ended 2026-06-30 |
| AEON | AEON Biopharma, Inc. | $7.89M | — | −$54.62MTTM ended 2026-06-30 |
| ACTU | ACTUATE THERAPEUTICS, INC. | $7.85M | — | −$20.45MTTM ended 2026-06-30 |
| TOVX | Theriva Biologics, Inc. | $7.80M | — | −$11.62MTTM ended 2026-06-30 |
| VTGN | Vistagen Therapeutics, Inc. | $7.54M | $2.50MTTM ended 2026-06-30 | −$67.62MTTM ended 2026-06-30 |
| ALZN | Alzamend Neuro, Inc. | $7.48M | — | −$9.10MTTM ended 2026-07-31 |
| SNGX | SOLIGENIX, INC. | $7.18M | — | −$8.83MTTM ended 2026-09-30 |
| MTVA | MetaVia Inc. | $7.18M | — | −$14.45MTTM ended 2026-06-30 |
| APRE | Aprea Therapeutics, Inc. | $7.03M | — | −$14.14MTTM ended 2026-09-30 |
| ENSC | Ensysce Biosciences, Inc. | $7.02M | $4.50MTTM ended 2026-06-30 | −$12.62MTTM ended 2026-06-30 |
| LEXX | Lexaria Bioscience Corp. | $6.89M | $194.00KTTM ended 2026-05-31 | −$7.73MTTM ended 2026-05-31 |
| LTRN | Lantern Pharma Inc. | $6.80M | — | −$18.65MTTM ended 2026-06-30 |
| KPRX | KIORA PHARMACEUTICALS INC | $6.64M | $0.00TTM ended 2025-12-31 | −$10.99MTTM ended 2026-06-30 |
| FBLG | FibroBiologics, Inc. | $6.37M | — | −$18.14MTTM ended 2026-06-30 |
| ENVB | Enveric Biosciences, Inc. | $6.27M | — | −$8.73MTTM ended 2026-06-30 |
| CNSP | CNS Pharmaceuticals, Inc. | $5.86M | — | −$16.70MTTM ended 2026-06-30 |
| XCUR | EXICURE, INC. | $5.83M | $0.00TTM ended 2026-06-30 | −$8.28MTTM ended 2026-06-30 |
| BGMS | Bio Green Med Solution, Inc. | $5.76M | $747.00KTTM ended 2025-12-31 | −$2.20MTTM ended 2026-06-30 |
| TPST | Tempest Therapeutics, Inc. | $5.38M | — | −$40.47MTTM ended 2026-06-30 |
| PCSA | Processa Pharmaceuticals, Inc. | $5.14M | — | −$13.44MTTM ended 2026-06-30 |
| PULM | Pulmatrix, Inc. | $5.11M | — | −$4.01MTTM ended 2026-06-30 |
| IMNN | Imunon, Inc. | $5.05M | — | −$14.72MTTM ended 2026-06-30 |
| ACXP | Acurx Pharmaceuticals, Inc. | $4.99M | — | −$7.51MTTM ended 2026-06-30 |
| TCRT | Alaunos Therapeutics, Inc. | $4.67M | $3.00KTTM ended 2026-06-30 | −$4.01MTTM ended 2026-06-30 |
| XBIO | Xenetic Biosciences, Inc. | $4.37M | $3.26MTTM ended 2026-06-30 | −$2.48MTTM ended 2026-06-30 |
| APUS | Apimeds Pharmaceuticals US, Inc. | $4.12M | — | −$58.17MTTM ended 2026-06-30 |
| CVKD | Cadrenal Therapeutics, Inc. | $3.57M | — | −$11.54MTTM ended 2026-06-30 |
| GRI | GRI Bio, Inc. | $3.39M | — | −$9.66MTTM ended 2026-06-30 |
| TRAW | Traws Pharma, Inc. | $3.38M | $2.79MTTM ended 2025-12-31 | −$21.57MTTM ended 2026-06-30 |
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $3.22M | $1.11MTTM ended 2026-06-30 | −$8.11MTTM ended 2026-06-30 |
| DRMA | Dermata Therapeutics, Inc. | $3.06M | — | −$8.37MTTM ended 2026-06-30 |
| MBIO | MUSTANG BIO, INC. | $2.99M | — | −$3.53MTTM ended 2026-09-30 |
| ERNA | Ernexa Therapeutics Inc. | $2.99M | — | −$13.96MTTM ended 2026-09-30 |
| KALA | KALA BIO, Inc. | $2.96M | $0.00TTM ended 2025-12-31 | −$10.08MTTM ended 2026-06-30 |
| REVB | REVELATION BIOSCIENCES, INC. | $2.43M | — | −$12.16MTTM ended 2026-09-30 |
| APVO | Aptevo Therapeutics Inc. | $2.29M | — | −$26.41MTTM ended 2026-06-30 |
| ONCO | Onconetix, Inc. | $2.15M | $645.82KTTM ended 2026-06-30 | −$10.20MTTM ended 2026-06-30 |
| JAGX | Jaguar Health, Inc. | $2.10M | $27.82MTTM ended 2026-06-30 | −$36.92MTTM ended 2026-06-30 |
| SILO | Silo Pharma, Inc. | $2.05M | $54.08KTTM ended 2026-06-30 | −$4.47MTTM ended 2026-06-30 |
| HCWB | HCW Biologics Inc. | $1.91M | $6.72MTTM ended 2026-06-30 | −$5.58MTTM ended 2026-06-30 |
| GNPX | Genprex, Inc. | $1.72M | — | −$16.50MTTM ended 2026-06-30 |
| JUNS | JUPITER NEUROSCIENCES, INC. | $1.64M | $40.45KTTM ended 2026-03-31 | −$9.20MTTM ended 2026-06-30 |
| OGEN | ORAGENICS INC | $1.58M | — | −$10.08MTTM ended 2026-06-30 |
| KPTI | Karyopharm Therapeutics Inc. | $1.36M | $146.62MTTM ended 2026-06-30 | −$224.74MTTM ended 2026-06-30 |
| GOVX | GeoVax Labs, Inc. | $1.16M | $0.00TTM ended 2026-06-30 | −$20.43MTTM ended 2026-06-30 |
| MTNB | Matinas BioPharma Holdings, Inc. | $1.14M | — | −$6.69MTTM ended 2026-06-30 |
| DCOY | Decoy Therapeutics Inc. | $733.81K | — | −$14.45MTTM ended 2026-06-30 |
| NXTS | Nexentis Technologies Inc. | $700.51K | $209.00KTTM ended 2025-09-30 | −$16.03MTTM ended 2026-06-30 |
| CDT | CDT Equity Inc. | $1.32K | — | −$37.15MTTM ended 2026-06-30 |
No matching companies.